Dr. Animesh Saha

• Certificate of Eligibility for Specialist Registration (CESR), UK - 2019
• Cyclotron Trust Award, PTCOG-58, Manchester, UK - 2019
• Member (MNAMS) of the National Academy of Medical Sciences (India) - 2018
• International training fellowship in St James University Hospital (Leeds Teaching Hospital), UK - 2018
• Fellowship in Clinical Oncology from Tata Medical Center, Kolkata, India - 2017
• FRCR in Clinical Oncology awarded by Royal College of Radiologists, London - 2018
• The Company of Biologists Travel Award, NCRI, Liverpool, UK - 2015
• 1st prize for poster presentation in controversies in clinical oncology which was held in Kolkata, India - 2016
• 2nd prize for oral presentation, AROICON West Bengal chapter - 2013

• Certificate of Eligibility for Specialist Registration (CESR), UK - 2019
• Cyclotron Trust Award, PTCOG-58, Manchester, UK - 2019
• Member (MNAMS) of the National Academy of Medical Sciences (India) - 2018
• International training fellowship in St James University Hospital (Leeds Teaching Hospital), UK - 2018
• Fellowship in Clinical Oncology from Tata Medical Center, Kolkata, India - 2017
• FRCR in Clinical Oncology awarded by Royal College of Radiologists, London - 2018
• The Company of Biologists Travel Award, NCRI, Liverpool, UK - 2015
• 1st prize for poster presentation in controversies in clinical oncology which was held in Kolkata, India - 2016
• 2nd prize for oral presentation, AROICON West Bengal chapter - 2013

He has published over 42 articles to date. Some of them are:

• Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?: A Systematic Review
• Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review
• Is it safe to use thoracic radiotherapy for the treatment of lung cancer patients with interstitial lung disease?
• 1476P Is it worth adding concurrent chemo-radiotherapy or radiotherapy on the top of neoadjuvant chemotherapy in the management of borderline resectable and locally advanced pancreatic adenocarcinoma? A systematic review
• 1476P Is it worth adding concurrent chemo-radiotherapy or radiotherapy on the top of neoadjuvant chemotherapy in the management of borderline resectable and locally advanced pancreatic adenocarcinoma? A systematic review
• MA03.09 Can Clinical Variables be used to Provide Better Follow up in Stereotactic Ablative Radiotherapy (SABR) Treated Lung Cancers?
• Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients
• Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR). - An analysis of UK’s largest cohort of lung SABR patients
• Early experience of maintenance durvalumab post chemoradiation (CRT) in stage III non-small cell lung cancer (NSCLC) across West Yorkshire network: from Expanded Access Programme (EAP) to routine clinical use
• Can Dosimetry Affect Overall Survival in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer Treated with Stereotactic Ablative Radiotherapy (SABR)? An Analysis of 1300 Patients
• Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center
• Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: Do pre-NACT ER/PR status act as better prognosticators?
• Evaluating the Need for Daily Image Guidance in Head and Neck Cancers Treated with Helical Tomotherapy: A Retrospective Analysis of a Large Number of Daily Imaging-based Corrections
• Expression of immunohistochemical markers in locally advanced breast carcinoma and their use as predictors of pathological response: A prospective analysis of a retrospective cohort. (EXIPAR study).
• A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum
• A randomized comparative study between neoadjuvant 5-fluorouracil and leukovorin versus 5-fluorouracil and cisplatin along with concurrent radiation in locally advanced carcinoma rectum